SGLT2 Inhibitors 2016: Year-End News Roundup

Slideshow

SGLT2 inhibitors made diabetes headlines this year by gaining FDA approval for cardiovascular indication. We highlight this news and more for 2016.

We present a review of developments in SGLT2 inhibitors for the year 2016 – from the EMPA-REG OUTCOMES trial to successful dual therapy treatments to FDA advisories and safety guidelines.See the slide legends for links to the article summaries.

Related Videos
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
Natalie McCormick, PhD | Credit: American College of Rheumatology
Related Content
Anjali Dixit, MD, MPH | Credit: Stanford Medicine

GLP-1 Receptor Agonists Not Linked to Post-Op Respiratory Complications

April 25th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: 2024 ACP Type 2 Diabetes Recommendations

April 19th 2024
Podcast
Carolyn J. Crandall, MD: Key Guideline Updates for Type 2 Diabetes

Carolyn J. Crandall, MD: Key Guideline Updates for Type 2 Diabetes

April 19th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

April 17th 2024
Podcast
Elena Christofides, MD | Credit: Endocrinology Associates

Insulin Glargine Biosimilar Demonstrates Bioequivalence to Originator for Type 2 Diabetes

April 13th 2024
Article
Manufacturing Costs for Diabetes Medicines Could Likely Be Lower | Image Credit: Harvard University

Manufacturing Costs for Diabetes Medicines Could Likely Be Lower, Study Finds

April 4th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.